FIELD: biotechnology.
SUBSTANCE: present invention relates to a composition for the production of a target polypeptide in a mammalian cell or tissue and a method of producing said polypeptide in a mammalian cell or tissue in vitro with the use of such a composition. This composition contains a composition in the form of nanoparticles, containing cationic lipid, fusogenic lipid, cholesterol and PEG lipid. This formulation contains a modified mRNA encoding the target polypeptide. Thus, mRNA is modified in such a way that the uridine is replaced with 1-methyl pseudouridine.
EFFECT: present invention makes it possible to increase the efficiency of delivery of mRNA to the target cell and at the same time to reduce the immune response.
14 cl, 3 dwg, 154 tbl, 98 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS AND USE THEREOF | 2012 |
|
RU2707251C2 |
| MODIFIED NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS AND THEIR APPLICATION | 2012 |
|
RU2648950C2 |
| 5'-CAP-TRINUCLEOTIDE COMPOUNDS OR 5'-CAP COMPOUNDS WITH LARGE NUMBER OF NUCLEOTIDES AND THEIR USE FOR RNA STABILIZATION, PROTEIN EXPRESSION AND IN THERAPY | 2019 |
|
RU2811940C2 |
| ANTICANCER RNA VACCINES | 2017 |
|
RU2768829C2 |
| RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | 2018 |
|
RU2790447C2 |
| POLYNUCLEOTIDES CODING INTERLEUKIN-12 (IL12), AND APPLICATIONS THEREOF | 2017 |
|
RU2769316C2 |
| ARTIFICIAL NUCLEIC ACID MOLECULES | 2013 |
|
RU2651498C2 |
| VACCINES BASED ON NUCLEIC ACIDS | 2015 |
|
RU2746406C2 |
| TRANS-REPLICATING RNA | 2017 |
|
RU2752580C2 |
| TREATMENT OF DISEASES RELATED WITH GENE DLG BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT OF DLG GENE | 2011 |
|
RU2611190C2 |
